Spero.jpg
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2020 16:45 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update
March 16, 2020 08:45 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection
March 11, 2020 08:30 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Closing of Rights Offering
March 05, 2020 16:01 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 28, 2020 17:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics to Present at March Investor Conferences
February 26, 2020 16:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Commencement of Rights Offering
February 11, 2020 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development
February 05, 2020 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2020 18:54 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Proposed Rights Offering
January 30, 2020 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...